Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-08 · accession 0001504783-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-12 | 2026-01-08 | NBIX | Lippoldt Darin | CLO | M - OptEx | $35.99 | +3,349 | 46.8K | +8% | +$120.5K |
| D | 2026-01-12 | 2026-01-08 | NBIX | Lippoldt Darin | CLO | M - OptEx | $0.00 | -3,349 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-08 | M | A | 3,349 | $35.99 | 46,754 | D | — | — | |
| 2 | Derivative | Incentive Stock Option | 2026-01-08 | M | D | 3,349 | $0.00 | 0 | D | $35.99 · — to 2026-02-05 | 3,349 Common Stock | (F1) The option was granted February 5, 2016 and vested monthly over four years. These options were due to expire on February 5, 2026. |